The acute effect of different NAD plus precursors included in the combined metabolic activators

Basit Öğe Kaydı
dc.authorid0000-0003-0352-1947
dc.contributor.authorLi, Xiangyu
dc.contributor.authorYang, Hong
dc.contributor.authorJin, Han
dc.contributor.authorTürkez, Hasan
dc.contributor.authorÖztürk, Gürkan
dc.contributor.authorDoğanay, Hamdi Levent
dc.contributor.authorZhang, Cheng
dc.contributor.authorNielsen, Jens
dc.contributor.authorUhlen, Mathias
dc.contributor.authorBoren, Jan
dc.contributor.authorMardinoğlu, Adil
dc.date.accessioned2023-09-11T07:30:09Z
dc.date.available2023-09-11T07:30:09Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü
dc.description.abstractNAD+ and glutathione precursors are currently used as metabolic modulators for improving the metabolic conditions associated with various human diseases, including non-alcoholic fatty liver disease, neurodegenerative diseases, mitochondrial myopathy, and age-induced diabetes. Here, we performed a one-day double blinded, placebo-controlled human clinical study to assess the safety and acute effects of six different Combined Metabolic Activators (CMAs) with 1 g of different NAD+ precursors based on global metabolomics analysis. Our integrative analysis showed that the NAD+ salvage pathway is the main source for boosting the NAD+ levels with the administration of CMAs without NAD+ precursors. We observed that incorporation of nicotinamide (Nam) in the CMAs can boost the NAD+ products, followed by niacin (NA), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not flush free niacin (FFN). In addition, the NA administration led to a flushing reaction, accompanied by decreased phospholipids and increased bilirubin and bilirubin derivatives, which could be potentially risky. In conclusion, this study provided a plasma metabolomic landscape of different CMA formulations, and proposed that CMAs with Nam, NMN as well as NR can be administered for boosting NAD+ levels to improve altered metabolic conditions.
dc.description.sponsorshipPoLiMeR Innovative Training Network (Marie Sklodowska-Curie Grant) - European Union's Horizon 2020 research and innovation program ; Knut & Alice Wallenberg Foundation ; Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) ; ScandiBio Therapeuticsen_US
dc.identifier.citationLi, X., Yang, H., Jin, H., Türkez, H., Öztürk, G., Doğanay, H. L. ... Mardinoğlu, A. (2023). The acute effect of different NAD plus precursors included in the combined metabolic activators. Free Radical Biology and Medicine, 205, 77-89. https://dx.doi.org/10.1016/j.freeradbiomed.2023.05.032
dc.identifier.doi10.1016/j.freeradbiomed.2023.05.032
dc.identifier.endpage89
dc.identifier.issn0891-5849
dc.identifier.issn1873-4596
dc.identifier.pmid37271226
dc.identifier.scopus2-s2.0-85161276991
dc.identifier.scopusqualityQ1
dc.identifier.startpage77
dc.identifier.urihttps://dx.doi.org/10.1016/j.freeradbiomed.2023.05.032
dc.identifier.urihttps://hdl.handle.net/20.500.12511/11401
dc.identifier.volume205
dc.identifier.wos001053802900001en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorÖztürk, Gürkan
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofFree Radical Biology and Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNAD+ Precursors
dc.subjectSerine
dc.subjectCysteine
dc.subjectCarnitine
dc.subjectMetabolomics
dc.subjectSystems Medicine
dc.titleThe acute effect of different NAD plus precursors included in the combined metabolic activators
dc.title.alternativeThe acute effect of different NAD+ precursors included in the combined metabolic activators
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Ozturk-Gurkan-2023.pdf
Boyut:
10.22 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu